CG Bio said Monday that it has obtained domestic sales right for the gastrointestinal ulcer therapy medical device, which contains epithelial cell growth factor.

This product is the world's first medical device of its kind, developed with the support by Korea Health Industry Development Institute. The treatment is used to treat wounds and bleeding from a hemorrhagic digestive ulcer, endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD).

In clinical trials, 76 patients with ulcer bleeding due to peptic ulcer, EMR, and ESD showed 100 percent early hemostasis proving the device’s safety and efficacy.

The company’s gastrointestinal ulcer treatment can be applied to a wide range of areas and has excellent absorbency, CG Bio _{시지바이오} said, adding that it is also possible to stop the bleeding with one injection immediately and reach the beginning and the end of the gastrointestinal tract that existing therapeutic agent had a hard time reaching.

It is also effective in small doses and comes out through the digestive tract within three for four days after the procedure.

“The treatment is easy to perform in an emergency because it has a simple procedure and shows an excellent hemostatic effect and wound protection effect on hemorrhage site,” said Yoo Hyun-seung _유현승, CEO of CG Bio. “It also is expected to serve as an excellent treatment for elderly patients, who can have massive hemorrhage due to associated diseases.”

CG Bio will do its best for the prompt release to the market of the gastrointestinal ulcer treatment material developed by domestic technology, Yoo added.